Parkinson's Disease-Associated LRRK2 Hyperactive Kinase Mutant Disrupts Synaptic Vesicle Trafficking in Ventral Midbrain Neurons
- PMID: 29054882
- PMCID: PMC5700420
- DOI: 10.1523/JNEUROSCI.0964-17.2017
Parkinson's Disease-Associated LRRK2 Hyperactive Kinase Mutant Disrupts Synaptic Vesicle Trafficking in Ventral Midbrain Neurons
Abstract
Parkinson's disease (PD) is characterized pathologically by the selective loss of substantia nigra (SN) dopaminergic (DAergic) neurons. Recent evidence has suggested a role of LRRK2, linked to the most frequent familial PD, in regulating synaptic vesicle (SV) trafficking. However, the mechanism whereby LRRK2 mutants contribute to nigral vulnerability remains unclear. Here we show that the most common PD mutation LRRK2 G2019S impairs SV endocytosis in ventral midbrain (MB) neurons, including DA neurons, and the slowed endocytosis can be rescued by inhibition of LRRK2 kinase activity. A similar endocytic defect, however, was not observed in LRRK2 mutant neurons from the neocortex (hereafter, cortical neurons) or the hippocampus, suggesting a brain region-specific vulnerability to the G2019S mutation. Additionally, we found MB-specific impairment of SV endocytosis in neurons carrying heterozygous deletion of SYNJ1 (PARK20), a gene that is associated with recessive Parkinsonism. Combining SYNJ1+/- and LRRK2 G2019S does not exacerbate SV endocytosis but impairs sustained exocytosis in MB neurons and alters specific motor functions of 1-year-old male mice. Interestingly, we show that LRRK2 directly phosphorylates synaptojanin1 in vitro, resulting in the disruption of endophilin-synaptojanin1 interaction required for SV endocytosis. Our work suggests a merge of LRRK2 and SYNJ1 pathogenic pathways in deregulating SV trafficking in MB neurons as an underlying molecular mechanism of early PD pathogenesis.SIGNIFICANCE STATEMENT Understanding midbrain dopaminergic (DAergic) neuron-selective vulnerability in PD is essential for the development of targeted therapeutics. We report, for the first time, a nerve terminal impairment in SV trafficking selectively in MB neurons but not cortical neurons caused by two PARK genes: LRRK2 (PARK8) and SYNJ1 (PARK20). We demonstrate that the enhanced kinase activity resulting from the most frequent G2019S mutation in LRRK2 is the key to this impairment. We provide evidence suggesting that LRRK2 G2019S and SYNJ1 loss of function share a similar pathogenic pathway in deregulating DAergic neuron SV endocytosis and that they play additive roles in facilitating each other's pathogenic functions in PD.
Keywords: LRRK2 G2019S; Parkinson's disease; dopamine neuron; genetic interaction; synaptic vesicle; synaptojanin1/synj1.
Copyright © 2017 the authors 0270-6474/17/3711366-11$15.00/0.
Figures
![Figure 1.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5700420/bin/zns9991702920001.gif)
![Figure 2.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5700420/bin/zns9991702920002.gif)
![Figure 3.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5700420/bin/zns9991702920003.gif)
![Figure 4.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5700420/bin/zns9991702920004.gif)
![Figure 5.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5700420/bin/zns9991702920005.gif)
![Figure 6.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5700420/bin/zns9991702920006.gif)
Similar articles
-
Selective expression of Parkinson's disease-related Leucine-rich repeat kinase 2 G2019S missense mutation in midbrain dopaminergic neurons impairs dopamine release and dopaminergic gene expression.Hum Mol Genet. 2015 Sep 15;24(18):5299-312. doi: 10.1093/hmg/ddv249. Epub 2015 Jun 29. Hum Mol Genet. 2015. PMID: 26123485 Free PMC article.
-
LRRK2 phosphorylation of auxilin mediates synaptic defects in dopaminergic neurons from patients with Parkinson's disease.Proc Natl Acad Sci U S A. 2018 May 22;115(21):5576-5581. doi: 10.1073/pnas.1717590115. Epub 2018 May 7. Proc Natl Acad Sci U S A. 2018. PMID: 29735704 Free PMC article.
-
Synj1 haploinsufficiency causes dopamine neuron vulnerability and alpha-synuclein accumulation in mice.Hum Mol Genet. 2020 Aug 11;29(14):2300-2312. doi: 10.1093/hmg/ddaa080. Hum Mol Genet. 2020. PMID: 32356558 Free PMC article.
-
Synaptic, Mitochondrial, and Lysosomal Dysfunction in Parkinson's Disease.Trends Neurosci. 2019 Feb;42(2):140-149. doi: 10.1016/j.tins.2018.11.001. Epub 2018 Nov 30. Trends Neurosci. 2019. PMID: 30509690 Free PMC article. Review.
-
Deregulation of autophagy and vesicle trafficking in Parkinson's disease.Neurosci Lett. 2019 Apr 1;697:59-65. doi: 10.1016/j.neulet.2018.04.013. Epub 2018 Apr 5. Neurosci Lett. 2019. PMID: 29627340 Free PMC article. Review.
Cited by
-
Advancements in Genetic and Biochemical Insights: Unraveling the Etiopathogenesis of Neurodegeneration in Parkinson's Disease.Biomolecules. 2024 Jan 5;14(1):73. doi: 10.3390/biom14010073. Biomolecules. 2024. PMID: 38254673 Free PMC article. Review.
-
Neurodevelopmental and synaptic defects in DNAJC6 parkinsonism, amenable to gene therapy.Brain. 2024 Jun 3;147(6):2023-2037. doi: 10.1093/brain/awae020. Brain. 2024. PMID: 38242634 Free PMC article.
-
Cellular and subcellular localization of Rab10 and phospho-T73 Rab10 in the mouse and human brain.Acta Neuropathol Commun. 2023 Dec 18;11(1):201. doi: 10.1186/s40478-023-01704-9. Acta Neuropathol Commun. 2023. PMID: 38110990 Free PMC article.
-
Disruption of Dopamine Homeostasis Associated with Alteration of Proteins in Synaptic Vesicles: A Putative Central Mechanism of Parkinson's Disease Pathogenesis.Aging Dis. 2024 May 7;15(3):1204-1226. doi: 10.14336/AD.2023.0821-2. Aging Dis. 2024. PMID: 37815908 Free PMC article. Review.
-
Inhibition of the Exocyst Complex Attenuates the LRRK2 Pathological Effects.Int J Mol Sci. 2023 Aug 10;24(16):12656. doi: 10.3390/ijms241612656. Int J Mol Sci. 2023. PMID: 37628835 Free PMC article.
References
-
- Arranz AM, Delbroek L, Van Kolen K, Guimarães MR, Mandemakers W, Daneels G, Matta S, Calafate S, Shaban H, Baatsen P, De Bock PJ, Gevaert K, Vanden Berghe P, Verstreken P, De Strooper B, Moechars D (2015) LRRK2 functions in synaptic vesicle endocytosis through a kinase-dependent mechanism. J Cell Sci 128:541–552. 10.1242/jcs.158196 - DOI - PubMed
-
- Beccano-Kelly DA, Kuhlmann N, Tatarnikov I, Volta M, Munsie LN, Chou P, Cao LP, Han H, Tapia L, Farrer MJ, Milnerwood AJ (2014) Synaptic function is modulated by LRRK2 and glutamate release is increased in cortical neurons of G2019S LRRK2 knock-in mice. Front Cell Neurosci 8:301. 10.3389/fncel.2014.00301 - DOI - PMC - PubMed
-
- Beccano-Kelly DA, Volta M, Munsie LN, Paschall SA, Tatarnikov I, Co K, Chou P, Cao LP, Bergeron S, Mitchell E, Han H, Melrose HL, Tapia L, Raymond LA, Farrer MJ, Milnerwood AJ (2015) LRRK2 overexpression alters glutamatergic presynaptic plasticity, striatal dopamine tone, postsynaptic signal transduction, motor activity and memory. Hum Mol Genet 24:1336–1349. 10.1093/hmg/ddu543 - DOI - PubMed
-
- Belluzzi E, Gonnelli A, Cirnaru MD, Marte A, Plotegher N, Russo I, Civiero L, Cogo S, Carrion MP, Franchin C, Arrigoni G, Beltramini M, Bubacco L, Onofri F, Piccoli G, Greggio E (2016) LRRK2 phosphorylates pre-synaptic N-ethylmaleimide sensitive fusion (NSF) protein enhancing its ATPase activity and SNARE complex disassembling rate. Mol Neurodegener 11:1. 10.1186/s13024-015-0066-z - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous